Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

Literature DB >> 8601328

In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

J Woo¹, W Cheung, R Chan, H S Chan, A Cheng, K Chan.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1996 PMID： 8601328 DOI： 10.1016/0009-9120(95)02024-1

Source DB: PubMed Journal: Clin Biochem ISSN： 0009-9120 Impact factor: 3.281

Keyword Cloud
Cited

× No keyword cloud information.

22 in total

1. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.

Authors: Sarita Rani; Avinash Gothwal; Pawan K Pandey; Devendra S Chauhan; Praveen K Pachouri; Umesh D Gupta; Umesh Gupta
Journal: Pharm Res Date: 2018-12-03 Impact factor: 4.200

2. Noninvasive ¹¹C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

Authors: Elizabeth W Tucker; Beatriz Guglieri-Lopez; Alvaro A Ordonez; Brittaney Ritchie; Mariah H Klunk; Richa Sharma; Yong S Chang; Julian Sanchez-Bautista; Sarah Frey; Martin A Lodge; Steven P Rowe; Daniel P Holt; Jogarao V S Gobburu; Charles A Peloquin; William B Mathews; Robert F Dannals; Carlos A Pardo; Sujatha Kannan; Vijay D Ivaturi; Sanjay K Jain
Journal: Sci Transl Med Date: 2018-12-05 Impact factor: 17.956

3. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors: Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191

4. Protein Binding of First-Line Antituberculosis Drugs.

Authors: Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal: Antimicrob Agents Chemother Date: 2018-06-26 Impact factor: 5.191

5. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors: Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal: Antimicrob Agents Chemother Date: 2009-05-18 Impact factor: 5.191

10. Absolute Quantification of Rifampicin by MALDI Imaging Mass Spectrometry Using Multiple TOF/TOF Events in a Single Laser Shot.

Authors: Boone M Prentice; Chad W Chumbley; Richard M Caprioli
Journal: J Am Soc Mass Spectrom Date: 2016-09-21 Impact factor: 3.109

In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

1. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.

2. Noninvasive ¹¹C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

3. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

4. Protein Binding of First-Line Antituberculosis Drugs.

5. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Review 6. Interethnic differences in pharmacokinetics of antibacterials.

7. Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

8. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

9. Prediction of Drug Penetration in Tuberculosis Lesions.

10. Absolute Quantification of Rifampicin by MALDI Imaging Mass Spectrometry Using Multiple TOF/TOF Events in a Single Laser Shot.